Related references
Note: Only part of the references are listed.Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients
G. D. Marijn Veerman et al.
CLINICAL PHARMACOKINETICS (2021)
Therapeutic drug monitoring of oral targeted antineoplastic drugs
Anna Mueller-Schoell et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake
Anne Keunecke et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients
Evelina Cardoso et al.
CLINICAL THERAPEUTICS (2020)
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical
Nikki S. IJzerman et al.
EUROPEAN JOURNAL OF CANCER (2020)
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
Koen G. A. M. Hussaarts et al.
PHARMACEUTICS (2020)
Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology
Stefanie L. Groenland et al.
CLINICAL PHARMACOKINETICS (2019)
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study
Stefanie L. Groenland et al.
THERAPEUTIC DRUG MONITORING (2019)
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine
Stefanie L. Groenland et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Merce Brunet et al.
THERAPEUTIC DRUG MONITORING (2019)
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
Femke M. de Man et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Clinically relevant drug interactions with multikinase inhibitors: a review
Koen G. A. M. Hussaarts et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Individualised medicine: why we need Bayesian dosing
Joni Donagher et al.
INTERNAL MEDICINE JOURNAL (2017)
The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology
Josephine A. Touma et al.
TRANSLATIONAL CANCER RESEARCH (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
Remy B. Verheijen et al.
CLINICAL PHARMACOKINETICS (2017)
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide
S. Bins et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
Remy B. Verheijen et al.
CLINICAL CANCER RESEARCH (2016)
Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer
Roelof W. F. van Leeuwen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
Jacqueline S. L. Kloth et al.
CLINICAL PHARMACOKINETICS (2015)
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
Djoeke de Wit et al.
DRUG DISCOVERY TODAY (2015)
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
N. A. G. Lankheet et al.
BRITISH JOURNAL OF CANCER (2014)
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors
Matthias Freiwald et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study
Jacqueline S. L. Kloth et al.
CLINICAL PHARMACOKINETICS (2014)
Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
M. H. M. Diekstra et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care
Nienke A. G. Lankheet et al.
THERAPEUTIC DRUG MONITORING (2014)
Therapeutic drug monitoring of antimicrobials
Jason A. Roberts et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
Karel Eechoute et al.
CLINICAL CANCER RESEARCH (2012)
Population pharmacokinetic analysis of sorafenib in patients with solid tumours
Lokesh Jain et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2
K. Eechoute et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Brett E. Houk et al.
CLINICAL CANCER RESEARCH (2009)
A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times
Yanfeng Wang et al.
THERAPEUTIC DRUG MONITORING (2009)
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
Catherine Delbaldo et al.
CLINICAL CANCER RESEARCH (2006)
Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation - A review
ME de Jonge et al.
CLINICAL PHARMACOKINETICS (2005)
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs
A Rousseau et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2002)
Share Paper
